임상시험 관리 시스템 시장 규모, 점유율과 동향 분석 보고서 : 솔루션 유형별, 제공 모드별, 컴포넌트별, 최종 용도별, 지역별, 부문 예측(2026-2033년)

Clinical Trials Management System (CTMS) Market Summary

The global clinical trials management system (CTMS) market size was estimated at USD 2.35 billion in 2025 and is projected to reach USD 7.40 billion, growing at a CAGR of 15.59% from 2026 to 2033. This growth is primarily driven by the accelerated adoption of digital solutions across clinical trials, increasing trial complexity, and the growing preference for decentralized and hybrid trial models.

In addition, strategic initiatives by key industry players such as technology upgrades, partnerships, and platform integrations combined with a steady rise in the number of clinical studies globally, are expected to further fuel market expansion. The growing volume of clinical trials is driving the growth of the clinical trial management system market, as sponsors and CROs require robust platforms to manage increasing study complexity, multi-site coordination, and regulatory documentation. For instance, according to Invest India, around 18,000 new clinical trials were registered in India in 2024, marking a 50% increase compared to 2023, highlighting the surge in trial activity.

Similarly, the number of registered studies with posted results in ClinicalTrials.gov from 2021 to 2025 has shown a steady year-on-year increase, reflecting growing regulatory emphasis on transparency and timely disclosure of clinical trial outcomes. This highlights stronger compliance with global reporting requirements and increased accountability among sponsors, while also reinforcing the need for digital systems that can efficiently track study milestones, results submission, and regulatory timelines.

In addition, increasing R&D investments by life science and medical device companies, coupled with the growing prevalence of acute & chronic disorders, are driving the surge in clinical trials. This trend is expected to boost the demand for solutions such as CTMS, facilitating efficient management of diverse clinical trials and ultimately improving patient outcomes.

Global Clinical Trials Management System Market Report Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global clinical trials management systems market report based on solution type, component, delivery mode, end-use, and region:

• Solution Type Outlook (Revenue, USD Million, 2021 - 2033)
• Enterprise
• Site
• Component Outlook (Revenue, USD Million, 2021 - 2033)
• Software
• Services
• Delivery Mode Outlook (Revenue, USD Million, 2021 - 2033)
• Web & Cloud Based
• On Premise
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical and Biotechnology Firms
• Medical Device Firms
• CROs & Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Solution Type
  • 1.1.2. Component
  • 1.1.3. Delivery mode
  • 1.1.4. End Use
  • 1.1.5. Regional scope
  • 1.1.6. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Solution type outlook
  • 2.2.2. Component outlook
  • 2.2.3. Delivery mode outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Clinical Trials Management System Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising number of clinical trials
    • 3.2.1.2. Increasing outsourcing of virtual or decentralized clinical trials
    • 3.2.1.3. Increasing demand for e-clinical solutions
    • 3.2.1.4. Integration of e-consent with other e-clinical solutions
    • 3.2.1.5. Rising number of virtual or decentralized clinical trials
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Rising data privacy and cybersecurity concerns
    • 3.2.2.2. Significant implementation costs
  • 3.2.3. Market opportunity analysis
  • 3.2.4. Market challenge analysis
• 3.3. Clinical Trials Management System Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape
• 3.4. Case Study Insights
• 3.5. Technology Overview
  • 3.5.1. Changing Technology & Adoption

Chapter 4. Clinical Trials Management System Market: Solution Type Estimates & Trend Analysis

• 4.1. Solution Type Market Share, 2025 & 2033
• 4.2. Segment Dashboard
• 4.3. Global Clinical Trials Management System Market by Solution Type Outlook
• 4.4. Descriptive Analysis
  • 4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.5. Enterprise
  • 4.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.6. Site
  • 4.6.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. Clinical Trials Management System Market: Component Estimates & Trend Analysis

• 5.1. Component Market Share, 2025 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Clinical Trials Management System Market by Component Outlook
• 5.4. Software
  • 5.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.5. Services
  • 5.5.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Clinical Trials Management System Market: Delivery Mode Estimates & Trend Analysis

• 6.1. Delivery Modes Market Share, 2025 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Clinical Trials Management System Market by Delivery Modes Outlook
• 6.4. On-Premises
  • 6.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 6.5. Web & Cloud-Based
  • 6.5.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 7. Clinical Trials Management System Market: End Use Estimates & Trend Analysis

• 7.1. Application Market Share, 2025 & 2033
• 7.2. Segment Dashboard
• 7.3. Global Clinical Trials Management System Market by Application Outlook
• 7.4. Pharmaceutical and Biotechnology Firms
  • 7.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 7.5. Medical Device Firms
  • 7.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 7.6. CROs & Others
  • 7.6.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 8. Clinical Trials Management System Market: Regional Estimates & Trend Analysis, By Solution Type, By Component, By Delivery Mode, By End Use

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. Denmark
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.8. Norway
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Singapore market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization 2025
• 9.3. Key company market share analysis, 2025
• 9.4. Company Profiles,
  • 9.4.1. IQVIA, Inc.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Medidata (Dassault Systemes)
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Oracle
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Datatrak International, Inc. (Rebranded as Fountayn in 2022)
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. SimpleTrials
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Ennov (Parexel's Informatics division separated to form Calyx in January 2021, and its Enterprise Technology division was acquired by Ennov in February 2024.)
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. RealTime Software Solutions, LLC
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Veeva Systems
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Wipro Limited
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. PHARMASEAL International Ltd.
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. Advarra Inc.
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. Clario (ERT and Bioclinica)
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Product benchmarking
    • 9.4.12.4. Strategic initiatives
  • 9.4.13. Merative
    • 9.4.13.1. Company overview
    • 9.4.13.2. Financial performance
    • 9.4.13.3. Product benchmarking
    • 9.4.13.4. Strategic initiatives
  • 9.4.14. Clinion
    • 9.4.14.1. Company overview
    • 9.4.14.2. Financial performance
    • 9.4.14.3. Product benchmarking
    • 9.4.14.4. Strategic initiatives
  • 9.4.15. Anju Software
    • 9.4.15.1. Company overview
    • 9.4.15.2. Financial performance
    • 9.4.15.3. Product benchmarking
    • 9.4.15.4. Strategic initiatives
  • 9.4.16. ICON, plc
    • 9.4.16.1. Company overview
    • 9.4.16.2. Financial performance
    • 9.4.16.3. Product benchmarking
    • 9.4.16.4. Strategic initiatives
  • 9.4.17. Suvoda LLC (in April 2025 merged with Greenphire)
    • 9.4.17.1. Company overview
    • 9.4.17.2. Financial performance
    • 9.4.17.3. Product benchmarking
    • 9.4.17.4. Strategic initiatives